

Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc.

Novo Nordisk Inc. has recalculated its 340B ceiling prices for the period Q3 2019 for the products listed below due to revisions made to its Medicaid pricing data, and submitted to CMS. Novo Nordisk Inc. has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on HRSA's public website to ensure transparency to all 340B Covered Entities regarding the recalculation for the products below.

Novo Nordisk Inc. has determined the credit amount owed to each affected Covered Entity. Novo Nordisk Inc. will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds for each affected Covered Entity. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or a check will be issued to a Covered Entity whose wholesaler account cannot be identified.

NDC	Product Description
00169-2800-15	SAXENDA
00169-3201-11	FIASP VIAL 100U/ML 10ML
00169-4060-12	VICTOZA 6 MG/ML 2X3 ML
00169-4060-13	VICTOZA 6 MG/ML 3X3 ML
00169-4132-12	OZEMPIC 0.25MG/0.5MG 6PC.NFPL
00169-4136-02	OZEMPIC 1MG 2X1.5ML 4PCS.NFPL

If a Covered Entity believes that it is due a refund and is not contacted by Apexus by July 15, 2022, it may contact Novo Nordisk Inc., at NNIBIDNOTIFICATION@novonordisk.com.